Court Sets Terms For Pfizer Damages Over Axed Lyrica IP

By Joanne Faulkner (July 30, 2021, 5:57 PM BST) -- The money the National Health Service and generic drug companies can claim back from Pfizer over an invalidated epilepsy drug patent should be assessed based on how much money they would have made if subsidiary Warner-Lambert had not threatened any infringement proceedings, a judge ruled Friday in London. 

High Court Judge Antony Zacaroli said in a decision on preliminary issues that the potential claims against Pfizer should work from the assumption that none of the series of threats of litigation was made. 

"It is important to distinguish between losses caused by the order itself, and losses caused by the existence of...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!